Trials on Leukemia and blood

CHARLYActive, not recruiting

Cyclophosphamide to Reduce Complications Following Haploidentical Stem Cell Transplantation

If non-Hodgkin lymphoma (NHL) cannot be controlled with standard therapy (refractory), a stem cell transplant from a compatible donor may be recommended. In a so-called haploidentical stem cell transplant, the immunological similarity between the donor and the recipient is lower, and rejection reactions may occur as a complication of the transplant. This risk could potentially be reduced by administering a high dose of the drug cyclophosphamide. The aim of the study is to investigate whether high-dose cyclophosphamide administered after a haploidentical stem cell transplant can prolong disease-free survival and reduce the risk of rejection reactions. Women and men aged 18–65 with relapsed or refractory NHL who are receiving a haploidentical allogeneic stem cell transplant are eligible to participate in this study.

18–65 years · Relapsed / refractory · Phase II

B-NHL 2013Recruiting

A study on the treatment protocol of the NHL-BFM and NOPHO Studien GruppenT for mature B-cell non-Hodgkin lymphoma and Burkitt leukemia in children and adolescents (B-NHL 2013)

Lymphomas and leukemias are malignant diseases of the blood cells that vary greatly in their presentation and prognosis. The aggressive subtypes spread rapidly and usually require prompt treatment, most often a combination of chemotherapy and an antibody. The goal of the B-NHL 2013 study is to investigate the efficacy of the antibody rituximab in addition to standard chemotherapy for aggressive mature B-cell non-Hodgkin lymphomas (B-NHL) and Burkitt leukemia (B-AL), and to compare it with the treatment currently in use. Patients who have been newly diagnosed with these diseases and are under 18 years of age are eligible to participate in the study.

0–18 years · First line · Phase III

INFORM RegistryRecruiting

INFORM Registry Study on Individualized Treatment for Patients with Recurrent Malignant Disease, with a Special Focus on Children and Adolescents

Many types of cancer can now be cured using modern treatment options. Nevertheless, relapses and progressive cancer remain a major challenge. The goal of the INFORM-REGISTER study is to use molecular genetic testing methods to gather information about tumor characteristics that can be used by treating physicians to inform future treatment decisions. Patients aged 0 to 40 with previously treated, treatment-resistant, or progressive cancer who no longer have any established curative treatment options available are eligible to participate in the study.

0–40 years · Relapsed / refractory · Phase IV

DALY 2-EURecruiting

DALY-2

The DALY-2 study aims to investigate whether, in patients with a relapse of an aggressive form of lymphoma (known as DLBCL), the body’s own modified immune cells (known as CAR-T cells) are more effective than chemotherapy.

18–70 years · Relapsed / refractory · Phase II

GOAL IIActive, not recruiting

GOAL II

The GOAL-II trial is investigating the efficacy of adding a new antibody to existing standard therapy in patients with relapsed aggressive lymphoma.

18–64 years · Relapsed / refractory · Phase II

frontMIND / MOR208C310Active, not recruiting

FRONTMIND

The FRONTMIND study is investigating whether adding an antibody (tafasitamab) and an immunomodulatory agent (lenalidomide) to the current standard of care improves treatment outcomes for aggressive lymphoma (B-NHL).

18–80 years · Phase III

SAL-AML-REG-BIORecruiting

Clinical Registry for Recording Disease Progression and Collecting Biological Samples from Patients with Acute Myeloid Leukemia (AML) by the Leukemia Study Group (SAL)

Acute myeloid leukemia (AML) requires intensive and often complex treatment, with treatment approaches and chances of cure varying depending on genetic alterations and the course of the disease. The goal of the SAL study is to establish a registry of patients with AML. As comprehensive a set of medical data as possible regarding disease characteristics and progression will be collected to advance our understanding of the disease and improve treatment options. Women and men aged 18 and older who have AML are eligible to participate. Patients with a specific form of AML, known as promyelocytic leukemia (APL), may also participate in the study.

18 years and older

KPS-R01Recruiting

A registry study on genetically determined cancer risk (cancer predisposition syndromes, CPS) to improve early detection and treatment (CPS-R01 Study)

People with cancer predisposition syndrome (KPS) have an increased lifetime risk of developing certain types of cancer. Consequently, early cancer detection is of great importance in the context of this condition, as it allows tumors to be identified at an early stage and treated as effectively as possible. The goal of the KPS-R01 study is the systematic collection of patient data in a registry. Women and men of any age with a confirmed cancer predisposition syndrome or a strong suspicion of KPS are eligible to participate.

0 years and older · First line · Phase IV

OptiMATeRecruiting

Is a reduced-intensity version of the current standard treatment sufficient for central nervous system lymphoma?

Lymphomas are malignant diseases of white blood cells that typically manifest in the blood and lymph nodes, but can also primarily affect the central nervous system (CNS) (PCNSL). This requires intensive treatment based on established treatment protocols. The goal of the OptiMATe study is to investigate whether a reduced-intensity therapy is just as effective as standard treatment according to the MATRix protocol and may cause fewer side effects. Women and men between the ages of 18 and 70 with PCNSL are eligible to participate in this study. The lymphoma must not be located outside the CNS.

18–70 years · First line · Phase III

BO43243 Recruiting

New bispecific antibody (mosunetuzumab) for the treatment of chronic lymphocytic leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is a malignant disease of the white blood cells (B lymphocytes) that requires treatment when symptoms appear; effective treatment options are available. However, the disease may relapse or fail to respond adequately to treatment (refractory). The bispecific antibody mosunetuzumab could be a new treatment option. The aim of this study is to investigate the safety and efficacy of mosunetuzumab alone and in combination with the drug venetoclax (already approved). Patients aged 18 and older with CLL who have already received treatment are eligible to participate in this study.

18 years and older · Relapsed / refractory · Phase I

Trials on Leukemia and blood110